Jump to content

2-Deoxy-D-glucose

From Wikipedia, the free encyclopedia
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.
2-Deoxy-d-glucose[1]
2-Deoxy-D-glucose
Names
IUPAC name
2-Deoxy-D-arabino-hexopyranose
Systematic IUPAC name
(4R,5S,6R)-6-(hydroxymethyl)oxane-2,4,5-triol
Other names
2-Deoxyglucose
2-Deoxy-d-mannose
2-Deoxy-d-arabino-hexose
2-DG
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
ECHA InfoCard 100.005.295 Edit this at Wikidata
EC Number
  • 205-823-0
UNII
  • InChI=1S/C6H12O5/c7-2-4-6(10)3(8)1-5(9)11-4/h3-10H,1-2H2/t3-,4-,5?,6+/m1/s1 checkY
    Key: PMMURAAUARKVCB-CERMHHMHSA-N checkY
  • O[C@H](C(CO)O[C@H](O)C1)[C@H]1O
Properties
C6H12O5
Molar mass 164.16 g/mol
Melting point 142 to 144 °C (288 to 291 °F; 415 to 417 K)
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
checkY verify (what is checkY☒N ?)

2-Deoxy-d-glucose is a glucose molecule which has the 2-hydroxyl group replaced by hydrogen, so that it cannot undergo further glycolysis. As such; it acts to competitively inhibit the production of glucose-6-phosphate from glucose at the phosphoglucoisomerase level (step 2 of glycolysis).[2] 2-Deoxyglucose labeled with tritium or carbon-14 has been a popular ligand for laboratory research in animal models, where distribution is assessed by tissue-slicing followed by autoradiography, sometimes in tandem with either conventional or electron microscopy.

2-DG is up taken by the glucose transporters of the cell.[3] Therefore, cells with higher glucose uptake, for example tumor cells, have also a higher uptake of 2-DG. Since 2-DG hampers cell growth, its use as a tumor therapeutic has been suggested, and in fact, 2-DG is in clinical trials.[4] It is not completely clear how 2-DG inhibits cell growth. The fact that glycolysis is inhibited by 2-DG, seems not to be sufficient to explain why 2-DG treated cells stop growing.[5] A synergistic effect between 2-DG and various other agents have been reported in the pursuit of anticancer strategies.[6][7][8] Because of its structural similarity to mannose, 2DG has the potential to inhibit N-glycosylation in mammalian cells and other systems, and as such induces ER stress and the Unfolded Protein Response (UPR) pathway.[9][10][11]

Use in optical imaging

2-DG has been used as a targeted optical imaging agent for fluorescent in vivo imaging.[12][13] In clinical medical imaging (PET scanning), fluorodeoxyglucose is used, where one of the 2-hydrogens of 2-deoxy-D-glucose is replaced with the positron-emitting isotope fluorine-18, which emits paired gamma rays, allowing distribution of the tracer to be imaged by external gamma camera(s). This is increasingly done in tandem with a CT function which is part of the same PET/CT machine, to allow better localization of small-volume tissue glucose-uptake differences.

Indian adoption for COVID-19 treatment

On May 8, 2021, the Drugs Controller General of India approved an oral formulation of 2-deoxy-D-glucose for emergency use as adjunct therapy in moderate to severe coronavirus patients.[14][15] The drug was developed by the DRDO along with Dr. Reddy's Laboratories, who jointly claimed via a press release, that the drug "helps in faster recovery of hospitalised patients and reduces supplemental oxygen dependence".[15][16][17] The Wire as well as The Hindu noted that the approval was based on poor evidence; no journal publication (or preprint) concerning efficacy and safety are yet available.[16][17]

See also

References

  1. ^ Merck Index, 11th Edition, 2886.
  2. ^ Wick, AN; Drury, DR; Nakada, HI; Wolfe, JB (1957). "Localization of the primary metabolic block produced by 2-deoxyglucose" (PDF). J Biol Chem. 224 (2): 963–969. doi:10.1016/S0021-9258(18)64988-9. PMID 13405925.
  3. ^ Laussel, Clotilde; Léon, Sébastien (December 2020). "Cellular toxicity of the metabolic inhibitor 2-deoxyglucose and associated resistance mechanisms". Biochemical Pharmacology. 182: 114213. doi:10.1016/j.bcp.2020.114213. PMID 32890467.
  4. ^ Pelicano, H; Martin, DS; Xu, RH; Huang, P (2006). "Glycolysis inhibition for anticancer treatment". Oncogene. 25 (34): 4633–4646. doi:10.1038/sj.onc.1209597. PMID 16892078. S2CID 22155169.
  5. ^ Ralser, M.; Wamelink, M. M.; Struys, E. A.; Joppich, C.; Krobitsch, S.; Jakobs, C.; Lehrach, H. (2008). "A catabolic block does not sufficiently explain how 2-deoxy-D-glucose inhibits cell growth". Proceedings of the National Academy of Sciences. 105 (46): 17807–17811. Bibcode:2008PNAS..10517807R. doi:10.1073/pnas.0803090105. PMC 2584745. PMID 19004802.
  6. ^ Cheng, Gang; Zielonka, Jacek; Dranka, Brian P.; McAllister, Donna; Mackinnon, A. Craig; Joseph, Joy; Kalyanaraman, Balaraman (2012-05-15). "Mitochondria-Targeted Drugs Synergize with 2-Deoxyglucose to Trigger Breast Cancer Cell Death". Cancer Research. 72 (10): 2634–2644. doi:10.1158/0008-5472.CAN-11-3928. ISSN 0008-5472. PMC 3700358. PMID 22431711.
  7. ^ Luo, Zhangyi; Xu, Jieni; Sun, Jingjing; Huang, Haozhe; Zhang, Ziqian; Ma, Weina; Wan, Zhuoya; Liu, Yangwuyue; Pardeshi, Apurva; Li, Song (March 2020). "Co-delivery of 2-Deoxyglucose and a glutamine metabolism inhibitor V9302 via a prodrug micellar formulation for synergistic targeting of metabolism in cancer". Acta Biomaterialia. 105: 239–252. doi:10.1016/j.actbio.2020.01.019. PMC 7105957. PMID 31958597.
  8. ^ Abebe, Felagot A.; Hopkins, Megan D.; Vodnala, Suraj N.; Sheaff, Robert J.; Lamar, Angus A. (2021-07-20). "Development of a Rapid In Vitro Screening Assay Using Metabolic Inhibitors to Detect Highly Selective Anticancer Agents". ACS Omega. 6 (28): 18333–18343. doi:10.1021/acsomega.1c02203. ISSN 2470-1343. PMC 8296616. PMID 34308064.
  9. ^ Kurtoglu, M.; Gao, N.; Shang, J.; Maher, J. C.; Lehrman, M. A.; Wangpaichitr, M.; Savaraj, N.; Lane, A. N.; Lampidis, T. J. (2007-11-07). "Under normoxia, 2-deoxy-D-glucose elicits cell death in select tumor types not by inhibition of glycolysis but by interfering with N-linked glycosylation". Molecular Cancer Therapeutics. 6 (11): 3049–3058. doi:10.1158/1535-7163.mct-07-0310. ISSN 1535-7163. PMID 18025288. S2CID 6315384.
  10. ^ Xi, Haibin; Kurtoglu, Metin; Liu, Huaping; Wangpaichitr, Medhi; You, Min; Liu, Xiongfei; Savaraj, Niramol; Lampidis, Theodore J. (2010-07-01). "2-Deoxy-d-glucose activates autophagy via endoplasmic reticulum stress rather than ATP depletion". Cancer Chemotherapy and Pharmacology. 67 (4): 899–910. doi:10.1007/s00280-010-1391-0. ISSN 0344-5704. PMC 3093301. PMID 20593179.
  11. ^ Defenouillère, Quentin; Verraes, Agathe; Laussel, Clotilde; Friedrich, Anne; Schacherer, Joseph; Léon, Sébastien (2019-09-03). "The induction of HAD-like phosphatases by multiple signaling pathways confers resistance to the metabolic inhibitor 2-deoxyglucose" (PDF). Science Signaling. 12 (597): eaaw8000. doi:10.1126/scisignal.aaw8000. ISSN 1945-0877. PMID 31481524. S2CID 201829818.
  12. ^ Kovar, Joy L.; Volcheck, William; Sevick-Muraca, Eva; Simpson, Melanie A.; Olive, D. Michael (2009). "Characterization and performance of a near-infrared 2-deoxyglucose optical imaging agent for mouse cancer models". Analytical Biochemistry. 384 (2): 254–262. doi:10.1016/j.ab.2008.09.050. PMC 2720560. PMID 18938129.
  13. ^ Cheng, Z., Levi, J., Xiong, Z., Gheysens, O., Keren, S., Chen, X., and Gambhir, S., Bioconjugate Chemistry, 17(3), (2006), 662-669
  14. ^ What is 2-deoxy-D-glucose (2-DG) and is it effective against Covid?, The Economic Times, 17 May 2021.
  15. ^ a b "DCGI approves anti-COVID drug developed by DRDO for emergency use". Press Information Bureau, Government of India. 2021-05-08. Retrieved 2021-05-09.
  16. ^ a b Borana, Ronak (2021-05-12). "India's Drug Regulator Has Approved DRDO's New COVID Drug on Missing Evidence". The Wire Science. Retrieved 2021-05-18.
  17. ^ a b Koshy, Jacob (2021-05-11). "Questions remain on DRDO's COVID drug". The Hindu. ISSN 0971-751X. Retrieved 2021-05-18.
Retrieved from "https://en.wikipedia.org/w/index.php?title=2-Deoxy-D-glucose&oldid=1224458051"